Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD

Dissociation encompasses distinct phenomena, some linked to esketamine treatment and potentially overlapping with psychosis symptoms. In a post hoc analysis of data from an open-label, phase 3 study of esketamine plus a newly initiated oral antidepressant in patients with treatment-resistant depression, dissociation was reported as an adverse event in 14.3% (109/764) of patients. CADSS scores generally aligned with investigator-reported dissociation severity, but no cutoff point reliably distinguished presence from absence of dissociation events. Hallucinations occurred in 5 patients, and no delusions were reported, indicating psychotic symptoms were uncommon.

Study at a glance

Abstract

BACKGROUND: "Dissociation" comprises distinct phenomena, some of which are associated with esketamine treatment and some may overlap with positive symptoms of psychosis. Relationships between dissociation and psychotic symptoms assessed by -clinician report vs conventional rating scales were investigated in a post hoc analysis of data from the initial treatment session in an -open-label, -long-term safety, phase 3 study of esketamine plus a newly initiated oral antidepressant in patients with treatment-resistant depression. METHODS: Adverse events of dissociation or psychosis were examined via investigator report and the Clinician Administered Dissociative States Scale (CADSS) and Brief Psychiatric Rating Scale-Plus, respectively, 40 minutes post first esketamine dose. The range of CADSS total scores associated with investigator-reported severity of dissociation was determined by equipercentile linking. Logistic regression models and receiver operating curve analysis explored the CADSS cutoff point for determining presence/absence of dissociation. Frequency of response to specific CADSS items was examined to investigate qualitative differences in the pattern of symptoms reported across investigator-reported levels of adverse event severity. RESULTS: Dissociation was reported as an adverse event in 14.3% (109/764) of patients. Severity of most CADSS items increased with the severity of investigator-reported dissociation. No CADSS cutoff point discriminated well between the presence and absence of dissociation events. Hallucinations were reported as adverse events in 5 patients; none reported delusions. CONCLUSIONS: CADSS scores and severity of dissociation adverse events move generally in the same direction; however, there is substantial variability in this relationship. No signature profile of dissociative experiences was revealed, and psychotic symptoms were uncommon. TRIAL REGISTRATION: Clinical Trials.gov identifier: NCT02497287.